This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armstrong, W. B. Articles by Meyskens, F. L. Search for Related Content PubMed PubMed Citation Articles by Armstrong, W. B. Articles by Meyskens, F. L., Jr.

Single-Dose Administration of Bowman-Birk Inhibitor Concentrate in Patients with Oral Leukoplakia¹

Departments of Otolaryngology [W. B. A.] and Medicine [J. A., C. E. M., F. L. M.], Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, and Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 [A. R. K., X. S. W.]

The Bowman-Birk inhibitor (BBI) is a soybean-derived serine protease inhibitor and a potential cancer chemopreventive agent for humans. In this Phase I clinical trial, BBI concentrate was administered as a single oral dose to 24 subjects with oral leukoplakia. Pharmacokinetics of BBI was analyzed, and subjects were monitored clinically for toxic effects. Subjects received between 25 and 800 chymotrypsin inhibitor units (CIU) of the compound in a dose escalation trial. BBI was taken up rapidly, and a metabolic product of BBI was excreted in the urine within 24–48 h. No clinical or laboratory evidence of toxicity was observed in the study. Protease activity was also measured in buccal cells to evaluate usefulness as a biomarker. Single-dose BBI concentrate administered up to 800 CIU was well tolerated and appeared to be nontoxic. Further investigation in Phase II clinical trials is being done.

This article has been cited by other articles:

				F. L. Meyskens Jr. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2038 - 2041. [Full Text] [PDF]

				E. T. Hawk and B. Levin Colorectal Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391. [Abstract] [Full Text] [PDF]

				S. M. Lippman and L. M. Matrisian Protease Inhibitors in Oral Carcinogenesis and Chemoprevention Clin. Cancer Res., December 1, 2000; 6(12): 4599 - 4603. [Full Text]

				W. B. Armstrong, A. R. Kennedy, X. S. Wan, T. H. Taylor, Q. A. Nguyen, J. Jensen, W. Thompson, W. Lagerberg, and F. L. Meyskens Jr. Clinical Modulation of Oral Leukoplakia and Protease Activity by Bowman-Birk Inhibitor Concentrate in a Phase IIa Chemoprevention Trial Clin. Cancer Res., December 1, 2000; 6(12): 4684 - 4691. [Abstract] [Full Text]

				X. S. Wan, L.-J. W. Lu, K. E. Anderson, J. H. Ware, and A. R. Kennedy Urinary Excretion of Bowman-Birk Inhibitor in Humans after Soy Consumption as Determined by a Monoclonal Antibody-based Immunoassay Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 741 - 747. [Abstract] [Full Text]